PATENT CLAIM ANALYSIS

Application Number: 16033636
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2020-01
Patent Classification: ["514", "210180"]

Abstract:
Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R 1 , R 2 , R 3 , X and Y are defined in the specification.

Claim (Index 33):
The method of  claim 31 , including administering a therapeutic amount of a therapeutic agent selected from the group consisting of Ribavirin, viral RNA-dependent-RNA polymeras inhibitors including favipiravir, Triazavirin, Remdesivir (GS-5734), monoclonal antibody therapies including, ZMapp, REGN3470-3471-3479, mAb 114, vaccines including, cAd3-EBOZ, rVSV-ZEBOV, small interfering RNAs and microRNAs and immunomodulators.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12702937', '13091895', '09669298', '11034635', '13121900']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8247364480059688
- 35 USC 102 Novelty (BERT): 0.5715481662271714
- Combined Prediction Score: 0.7994176198280891
- Mean Citation Score: 332.16656
- Max Citation Score: 360.32703
- Similarity Product: 215.2546676936567

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test